News

Older multiple myeloma patients who are unable to receive a stem cell transplant could receive Ninlaro (ixazomib) as part of their first line-therapy instead…

A triple combination treatment — dendritic cell vaccination plus Revlimid (lenalidomide) and an anti-PD-1 checkpoint inhibitor — led to stronger anti-tumor immune responses against myeloma…

Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy…

Multiple myeloma patients whose cancer progresses early after first-line therapy have a greater economic burden compared to those whose disease progresses later, a recent study…

Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple…

Prescribing information for Kyprolis (carfilzomib) in the U.S. will now include positive survival data from the ASPIRE Phase 3 clinical trial, which found treatment significantly…

Genetic analysis of multiple myeloma DNA from two different sources present in blood samples provides researchers equally relevant cancer information as more invasive bone marrow…

Adding Empliciti (elotuzumab) to a combination of Pomalyst (pomalidomide) and dexamethasone significantly delays disease worsening or death in myeloma patients who failed to respond to previous treatment,…

A Phase 1b trial testing a combination of Reolysin (pelareorep), Velcade (bortezomib) and dexamethasone in multiple myeloma patients who failed to respond to previous therapy…

While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in the noncoding regions of our…